Independently Verified Semaglutide Clinics

The GLP-1 Market Is Booming. The Information Is Not.

Semaglutide and related GLP-1 medications have fundamentally changed how weight management works for millions of Americans. Wegovy's approval in 2021, the compounded semaglutide market that followed, and the arrival of tirzepatide have collectively created the largest new category in outpatient medicine in a generation. By early 2026, an estimated 15 million Americans were on a GLP-1 medication for weight management.

The market around that demand is a different story. Weight loss clinics have proliferated faster than any accountability infrastructure to evaluate them. A patient in Dallas searching for semaglutide will encounter dozens of providers within driving distance — med spas, direct primary care practices, telehealth platforms, internal medicine offices, and aesthetics clinics — with pricing that ranges from $99 to $400 per month for what appears to be the same medication. Most clinics do not publish their ongoing monthly costs. Many do not disclose which compounding pharmacy supplies their medication. Some charge consultation fees only visible on line-item invoices.

Insurance coverage is equally opaque. Whether your carrier covers branded Wegovy for weight loss depends on whether you have employer-sponsored insurance or a Marketplace plan, which carrier you have, which specific plan your employer selected, and whether your BMI meets the threshold. Calling your insurer's main line often produces incorrect information — the pharmacy benefits line is different, and the answers are different.

SemaVerified exists because patients making a $3,000-to-$5,000-per-year treatment decision deserve real data. We research and publish what we find. We do not accept payment from clinics for inclusion, placement, or favorable treatment. Our editorial policy and methodology are documented and publicly available.

What We Do Differently

Most semaglutide clinic listings are one of two things: paid directories where clinics purchase placement, or generic aggregators pulling from public databases without any direct verification. SemaVerified is neither.

We contact every clinic we cover directly. We verify their Texas Medical Board license status (or equivalent state board). We document the cash-pay pricing they actually charge, including promotional pricing, post-promotional pricing, and whether bundled services like labs or consultations are included. We ask which compounding pharmacy supplies their medication and whether that pharmacy holds FDA 503B registration. We note monitoring frequency, whether the prescriber is a physician, nurse practitioner, or physician assistant, and whether the clinic assists with insurance prior authorization.

This is not a quick process. It is the process that produces data worth trusting.

Find Verified Clinics Near You

SemaVerified currently covers the Dallas-Fort Worth metroplex, with additional metros in active research. Each metro hub includes a full clinic dataset, city-by-city pricing, insurance coverage by local carrier, and eligibility guides specific to that market.

Dallas-Fort Worth is our first verified metro. The DFW dataset covers 40 clinics across Dallas, Fort Worth, Plano, Frisco, Southlake, Farmers Branch, and surrounding cities. Every clinic was contacted directly for pricing, and each has been checked against the Texas Medical Board license database. The DFW hub is the most complete picture of a semaglutide market currently available.

Go to the DFW Hub →

Our 5-Step Verification Process

Every clinic in the SemaVerified database goes through the same five-step process before it is published. We do not list clinics that decline to provide pricing or that we cannot independently confirm hold an active medical license. As of March 2026, we have declined to publish information on 6 DFW clinics that met one or both exclusion criteria.

Step 1: State Medical Board License Check

We verify that the prescribing provider — whether a physician, nurse practitioner, or physician assistant — holds an active, unrestricted license with the Texas Medical Board (or equivalent state board for future metro coverage). We check license status, expiration date, and whether any disciplinary actions are on record. Clinics where the prescribing provider could not be identified, or where the identified provider's license was lapsed or restricted, are excluded. Approximately 8% of clinics we have researched in DFW had a licensing issue requiring follow-up before publication.

Step 2: Pricing Transparency Assessment

We document the actual monthly cash-pay cost for semaglutide at maintenance dose — not the promotional introductory price, and not a price range so wide it communicates nothing. We note the consultation fee, lab work costs, and any required add-ons like supplement injections or monitoring visits. We flag clinics that advertise a low monthly number but bundle required costs separately. Of the 40 DFW clinics in our database, only 8 publish truly all-inclusive pricing without any add-on fees. The remaining 32 have pricing that requires a direct conversation to confirm the actual total monthly cost.

Step 3: Medication Sourcing Verification

We ask every clinic which compounding pharmacy supplies their semaglutide, and whether that pharmacy holds 503B outsourcing facility registration with the FDA. This matters because 503B facilities operate under significantly more rigorous FDA oversight than 503A compounding pharmacies, including product testing, sterility standards, and regular inspection. The FDA's 2024 testing of compounded semaglutide products found that 20% of samples contained lower-than-labeled active ingredient concentrations — a quality issue concentrated in less-regulated compounding facilities. We document the answer, publish it where provided, and note when a clinic declined to disclose its compounding pharmacy.

Step 4: Patient Monitoring Review

Semaglutide carries real clinical risks — gastrointestinal side effects, potential thyroid concerns (contraindicating it in patients with personal or family history of medullary thyroid carcinoma), and the need for dose titration. We document each clinic's monitoring frequency (monthly vs. weekly), whether follow-up visits are in-person or virtual, whether baseline lab work is required before starting treatment, and whether the clinic has a protocol for managing side effects. Clinics that sell semaglutide without any documented monitoring structure are flagged in our dataset.

Step 5: Reputation Analysis

We review publicly available patient feedback across Google, Yelp, and Healthgrades, with specific attention to complaints related to pricing surprises, billing practices, difficulty obtaining refunds, and medication quality concerns. We do not use star ratings as a primary quality indicator — high ratings are easily manufactured, and a clinic's ability to respond to a GI complication at 11pm matters more than its Google score. We look for patterns in negative reviews that suggest systemic problems, and we document review counts and rating distributions for each clinic in our dataset.

Read the full methodology →

What You Will Find on SemaVerified

Every content category on SemaVerified is built from primary research — direct clinic outreach, carrier formulary reviews, and on-the-ground pricing verification. We do not aggregate content from other sites. We do not publish claims we cannot source.

All content is reviewed by Dr. Sarah Mitchell, PharmD, and updated at minimum quarterly. Pricing data for active metros is verified monthly via direct clinic outreach. Our editorial independence is unconditional — content is never modified because a clinic complained, and no clinic is listed or excluded based on commercial considerations. See our editorial policy for the full commitment.

Why Trust SemaVerified

The GLP-1 market has a trust problem. Patients searching for semaglutide information encounter a landscape dominated by paid placements, clinic-sponsored content, and affiliate-driven directories where the ranking reflects the marketing budget of the clinic, not its quality. SemaVerified was built with a single operating principle: the data is trustworthy, or the platform has no purpose.

Medical Review

All content on SemaVerified is reviewed by Dr. Sarah Mitchell, PharmD, a clinical pharmacist with specialization in metabolic medications. Dr. Mitchell reviews pricing content for clinical accuracy, verifies that medication sourcing information is correctly characterized, and reviews eligibility and contraindication guidance before publication. Her role is editorial review, not endorsement. She receives a flat fee for her time and has no financial stake in any clinic listed on this platform.

Editorial Independence

No clinic pays for inclusion in SemaVerified. No clinic pays for favorable placement, a higher verification score, or removal of factual negative information. Clinics that contact us to negotiate their listing receive a standard response directing them to our editorial policy page. We have had two such contacts since launching the Dallas-Fort Worth hub in March 2026. Both were declined. This policy is not aspirational — it is structural. Our revenue model does not depend on clinic relationships.

Data-Driven by Default

Every pricing figure published on SemaVerified is sourced from a specific, verifiable data point: a published pricing page, a direct quote from clinic staff, or a recorded phone inquiry. We do not publish "approximate" or "estimated" ranges. When a clinic does not publish its pricing and does not provide it on direct outreach, we note the absence rather than filling the gap with a guess. Price transparency is itself a data point about how a clinic operates.

Pricing and coverage data changes. We verify DFW pricing monthly and publish the verification date on every page. When data is older than 60 days, we mark it as requiring re-verification and contact the clinic before publishing updated figures. The date on every page is the date of last verification, not the date of original publication.

Compounding Pharmacy Disclosure Policy

We ask every clinic which FDA-registered 503B compounding pharmacy supplies their semaglutide. We publish the answer if provided and note the non-disclosure if not. We do not make recommendations about specific compounding pharmacies, but we report which clinics source from 503B-registered facilities (higher oversight) versus 503A pharmacies or undisclosed sources. This single data point is among the most important quality indicators for a patient choosing a compounded semaglutide provider — and it is systematically absent from every other semaglutide information source we are aware of.

Read our full editorial policy →

About SemaVerified

SemaVerified launched in March 2026 with the Dallas-Fort Worth metro as its first verified market. The platform exists because the GLP-1 market had grown large enough to warrant serious independent data — and no such resource existed with the editorial standards and verification depth that a $3,000-per-year treatment decision demands.

Our mission is narrow and specific: give patients accurate, verified, independently produced information about semaglutide and GLP-1 clinics in their market. We are not a telehealth platform. We do not prescribe. We do not sell leads to clinics. We produce and publish research.

SemaVerified covers one GLP-1 medication class across one disease indication — obesity and weight management. We do not cover semaglutide for type 2 diabetes management beyond where that coverage is directly relevant to patient cost (for example, insurer formulary differences between Ozempic and Wegovy). We do not cover other anti-obesity medications. We cover what we can verify to a standard we believe is useful.

We expand to a new metro only when we have completed direct outreach to a sufficient number of clinics to produce a meaningful dataset. We do not launch placeholder metro pages. If a city is not listed in our metro index, we have not yet completed verification for it. Houston, Phoenix, and Austin are in active research as of March 2026.

Contact

For editorial inquiries, corrections, or data disputes: editorial@semaverified.com
For methodology questions: see our full methodology page
For clinic submissions: clinics interested in being included in a future metro dataset can submit basic information for research consideration. Submission does not guarantee inclusion and confers no commercial relationship.